PVantage™ Safety Data Automation
Pharmacovigilance Adverse Event Management Platform
PVantage is a modular offering, able to scale with your program as case volume increases.
PVantage™ is an innovative platform, that allows drug safety teams to streamline and automate case processing activities to ensure accuracy, efficiency, and compliance. This tool works with clinical trial and post market safety data and provides the ability to integrate, analyze, and visualize patient, program, and drug class information for greater control and oversight of your safety data.
PVantage is a proprietary cloud-based solution that allows Sponsors to elect the degree of automation of all workflows for case intake, case processing, safety data analysis and generation of standard reports. A dedicated, virtual managed environment provides Sponsors with a consistently updated platform and assures compliance with ever-changing global pharmacovigilance regulations.
Click to learn more about Comprehensive Safety Solutions to accompany this technology.
Allows for the automation and streamlining of case intake, including autopopulation of case data from a variety of sources
This module enables efficient and seamless data exchange between the Clinical electronic data capture (EDC) system and the Safety database, resulting in time reduction for case processing and data reconciliation while providing increases in quality.
PVantage dashboards allow for the visualization of complex safety data, making it easier to understand and interpret the data using a wide range of visualization options. The customizable data visualization layer allows for near real-time data inquiry and more informed decisions. In addition, sponsors can customize reporting content and cadence, including status reports, cumulative safety listings, KPIs, and other compliance reports.
With PVantage, Sponsors gain an accelerated technological advantage with greater visualization and efficient reporting of safety data.
Suggested For You
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
news
November 8th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure
perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies
perspectives
October 22nd, 2024
Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development
perspectives
October 15th, 2024
Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens
news
October 15th, 2024
MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)
perspectives
October 8th, 2024
Diversity Action Plan Guidance Part I: Implications for Sponsors
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules